IL6 and Cirrhosis: Since IL‐6 inherently elicits a central role in propagating systemic inflammation in cirrhosis and is indeed substantially correlated to decreased HRV indices, whether treatment with tocilizumab, a monoclonal antibody targeting IL‐6, can restore decreased HRV to its normal range is an area of further investigation.